Methods:

Five-year (2013–2017) review of coagulopathic trauma patients at our Level-I trauma center who received 3-or 4-PCC. Patients were divided into two groups (4-PCC and 3-PCC) and matched in 1: 1 ratio using propensity-score-matching for demographics, injury parameters, admission vitals, and hematological parameters. Primary outcomes were time to correction of international normalized ratio (INR), blood products transfusion, thromboembolic complications, and mortality. Secondary outcomes were hospital-length of stay (LOS), intensive care unit (ICU)-LOS, cost of therapy, and total hospital cost.

Results:

Six hundred fifty-seven patients met inclusion criteria of whom 250 patients (4-PCC: 125; 3-PCC: 125) were matched. The mean age was 50±19.4 y, 64% were male, and median-injury severity score was 24 [15–33]. 4-PCC was associated with accelerated correction of INR (365 vs. 428 min, P= 0.01), decrease in red blood cells (7 units vs. 10 units, P= 0.04) and FFP (6 units vs. 8 units, P= 0.03) transfused. There was no difference in platelet transfusion, thromboembolic complications, mortality, hospital, and ICU-LOS. 4-PCC was associated with higher cost of PCC therapy, and lower cost of transfusion. There was no difference regarding the total hospital cost between the two groups.

Conclusion:

Compared with 3-factor PCC, the use of 4-factor PCC is associated with a rapid reversal of INR and reduction in transfusion requirement without increasing the overall hospital cost or the risk of thromboembolic events. 4-PCC may be preferred as an adjunct for the resuscitation of coagulopathic trauma patients.